← Back to Search

Interleukin-1 (IL-1) Inhibitor

anakinra for Mucopolysaccharidosis

Q: How is anakinra typically employed in medical settings?

<p>Systemic juvenile idiopathic <a href="https://www.withpower.com/clinical-trials/arthritis">arthritis</a> (<a href="https://www.withpower.com/clinical-trials/sjia">sjia</a>) is most often treated with the medication anakinra. However, anakinra can also help patients manage neonatal-onset multisystem inflammatory disease (NOMID), receptors, interleukin-1, and steroids.</p>

Phase 2 & 3

Waitlist Available

Led By Lynda Polgreen, MD, MS

Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 8 weeks of treatment

Awards & highlights

Study Summary

This trial is testing whether a drug called anakinra can help treat symptoms in children with Sanfilippo syndrome, a disorder that causes progressive, irreversible neurodegeneration.

Eligible Conditions

Mucopolysaccharidosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 8 weeks of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 8 weeks of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8 weeks of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The percent of participants who required an increase in anakinra dose from 100 mg SC daily to 200 mg SC daily at Week 8 or Week 16

Side effects data

From 2017 Phase 2 trial • 33 Patients • NCT02278562

14%

right side weakness

14%

access related

14%

arrhythmia

100%

80%

60%

40%

20%

Study treatment Arm

Placebo 1 and 2

Actos

Anakinra

Trial Design

1Treatment groups

Experimental Treatment

Group I: treatmentExperimental Treatment1 Intervention

anakinra 100 mg subcutaneous once daily

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

anakinra

2012

Completed Phase 3

~240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Cure Sanfilippo FoundationUNKNOWN

1 Previous Clinical Trials

175,000 Total Patients Enrolled

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor

101 Previous Clinical Trials

46,277 Total Patients Enrolled

Swedish Orphan BiovitrumIndustry Sponsor

92 Previous Clinical Trials

12,490 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you give some examples of other research that has been done on anakinra?

"There are currently 34 active clinical trials studying anakinra, 6 of which have reached Phase 3. Many of these studies originate from Paris and Ile-De-France; however, 440 different locations around the world are running similar investigations."

Answered by AI

How is anakinra typically employed in medical settings?

"Systemic juvenile idiopathic arthritis (sjia) is most often treated with the medication anakinra. However, anakinra can also help patients manage neonatal-onset multisystem inflammatory disease (NOMID), receptors, interleukin-1, and steroids."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Open-label Study of Anakinra in MPS III

2020. "Open-label Study of Anakinra in MPS III". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04018755.